ReviewInternational journal of molecular sciences2021
New Insights into the Role of PD-1 and Its Ligands in Allergic Disease.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Anti-programmed Death-ligand 1 Antibody-associated Eosinophilic Granulomatosis with Polyangiitis in Non-small Cell Lung Cancer.Internal medicine (Tokyo, Japan) · 2026Article
- Fucosyltransferases in asthma: regulators of epithelial dysfunction, senescence, and airway inflammation.Clinical reviews in allergy & immunology · 2026Review
- Integrative Multi-Omics Analysis Characterizes Immune Dysregulation and Altered CD4Biomedicines · 2026Article
- Efficacy and Safety of the PD-1 Agonist JNJ-67484703 in Participants with Atopic Dermatitis: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Results.Dermatology and therapy · 2026Article
- Review
- Cytokines and immunologic checkpoint molecules in predicting success of allergen immunotherapy.Scientific reports · 2026Article
- Involvement of the PD-1 pathway in the modulation of immune responses during allergic diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Frequencies of PD-1 and LAG-3 positive T cells in asthmatic children and their relationship with inflammatory cytokines.Open medicine (Warsaw, Poland) · 2026Article
- Immune Modulatory Effects of PD-1/PD-L1 in Myasthenia Gravis: Insights From Peripheral Blood Mononuclear Cell Analysis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Osteopontin protects from ovalbumin-induced asthma by preserving the microbiome and the intestinal barrier function.mSystems · 2025Article
- Rocaglamide Suppresses Allergic Reactions by Regulating IL-4 Receptor Signaling.Molecules (Basel, Switzerland) · 2025Article
- The role of ILC2s in asthma combined with atopic dermatitis: bridging the gap from research to clinical practice.Frontiers in immunology · 2025Review
- Fecal microbiota transplantation alleviates food allergy in neonatal mice via the PD-1/PD-L1 pathway and change of the microbiota composition.The World Allergy Organization journal · 2024Article
- Bacterial sepsis causes more dramatic pathogenetic changes in the Th1 pathway than does viral (COVID-19) sepsis: a prospective observational study of whole blood transcriptomes.Virology journal · 2024Observational
- CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy.Clinical reviews in allergy & immunology · 2024Review
- The Exploitation of the Glycosylation Pattern in Asthma: How We Alter Ancestral Pathways to Develop New Treatments.Biomolecules · 2024Review
- Article
- Mononuclear cell composition and activation in blood and mucosal tissue of eosinophilic esophagitis.Frontiers in immunology · 2024Article
- Evaluation of PD-1 T lymphocytes in bronchoalveolar lavage in lung cancer compared to benign lung diseases.Clinical and experimental medicine · 2023Article
- Immune checkpoint molecules in prevention and development of asthma.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed cell death 1 (PD-1) and its ligands PD-L1 and PD-L2 are receptors that act in co-stimulatory and coinhibitory immune responses. Signaling the PD-1/PD-L1 or PD-L2 pathway is essential to regulate the inflammatory responses to infections, autoimmunity, and allergies, and it has been extensively studied in cancer. Allergic diseases include asthma, rhinoconjunctivitis, atopic dermatitis, drug allergy, and anaphylaxis. These overactive immune responses involve IgE-dependent activation and increased CD4+ T helper type 2 (Th2) lymphocytes. Recent studies have shown that PD-L1 and PD-L2 act to regulate T-cell activation and function. However, the main role of PD-1 and its ligands is to balance the immune response; however, the inflammatory process of allergic diseases is poorly understood. These immune checkpoint molecules can function as a brake or a kick-start to regulate the adaptive immune response. These findings suggest that PD-1 and its ligands may be a key factor in studying the exaggerated response in hypersensitivity reactions in allergies. This review summarizes the current understanding of the role of PD-1 and PD-L1 and PD-L2 pathway regulation in allergic diseases and how this immunomodulatory pathway is currently being targeted to develop novel therapeutic immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.